$0.439
-0.009 (-2.09%)終値時点
ONCY の同業比較
In the context of the broader market, ONCY competes directly with industry leaders such as ELOX and INKT. With a market capitalization of $57.34M, it holds a leading position in the sector. When comparing efficiency, ONCY's gross margin of N/A stands against ELOX's N/A and INKT's N/A. Such benchmarking helps identify whether Oncolytics Biotech Inc is trading at a premium or discount relative to its financial performance.
Oncolytics Biotech Inc の財務パフォーマンス
Oncolytics Biotech has reported significant losses, with net income for Q2 2026 at -13,073,616.56 USD and a forward P/E ratio of 45.45, indicating high valuation expectations despite ongoing negative earnings.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+101.67%
-12.99M
Operating Profit
FY2026Q2
YoY:
+78.94%
-13.07M
Net Income after Tax
FY2026Q2
YoY:
+37.50%
-0.11
EPS - Diluted
FY2026Q2
YoY:
+98.22%
-11.27M
Free Cash Flow
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。